<SEC-DOCUMENT>0000950103-21-007083.txt : 20210512
<SEC-HEADER>0000950103-21-007083.hdr.sgml : 20210512
<ACCEPTANCE-DATETIME>20210512075521
ACCESSION NUMBER:		0000950103-21-007083
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20210505
FILED AS OF DATE:		20210512
DATE AS OF CHANGE:		20210512

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ADC Therapeutics SA
		CENTRAL INDEX KEY:			0001771910
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			V8
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39071
		FILM NUMBER:		21913510

	BUSINESS ADDRESS:	
		STREET 1:		BIOPOLE
		STREET 2:		ROUTE DE LA CORNICHE 3B
		CITY:			EPALINGES
		STATE:			V8
		ZIP:			1066
		BUSINESS PHONE:		41 21 653 02 00

	MAIL ADDRESS:	
		STREET 1:		BIOPOLE
		STREET 2:		ROUTE DE LA CORNICHE 3B
		CITY:			EPALINGES
		STATE:			V8
		ZIP:			1066
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>dp150904_6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 3.5pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 6-K<BR>
<BR></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6.85pt; text-align: center; text-indent: -6.85pt"><B>REPORT OF FOREIGN
PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6.85pt; text-align: center; text-indent: -6.85pt">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6.85pt; text-align: center; text-indent: -6.85pt">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">For the month of
May 2021.</FONT></P>

<HR NOSHADE ALIGN="CENTER" STYLE="width: 21%; color: black">

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>Commission File
Number: 001-39071</B></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 22pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ADC Therapeutics SA</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Exact name of registrant as specified in its
charter)</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 12pt"><B>Biop&ocirc;le</B></FONT></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 12pt"><B>Route de la Corniche
3B</B></FONT></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 12pt"><B>1066 Epalinges</B></FONT></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 12pt"><B>Switzerland</B></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>(Address of principal
executive office)</B></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">Indicate by check
mark whether the registrant files or will file annual reports under cover of Form&nbsp;20-F or Form 40-F:</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="2" CELLPADDING="2" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; width: 70%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 29%; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">Form 20-F</FONT></TD>
    <TD STYLE="width: 14%"><P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&#9746;</FONT></P></TD>
    <TD STYLE="width: 15%; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 28%; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">Form 40-F</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 14%"><FONT STYLE="font-size: 10pt"></TD></TR>
  </TABLE>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>SIGNATURE</B></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="2" CELLPADDING="2" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt"><B>ADC Therapeutics SA</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Date: May 12, 2021</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 51%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 7%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="width: 42%; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Michael Forer</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Michael Forer</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Executive Vice President &amp; General Counsel</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>EXHIBIT INDEX</B></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="2" CELLPADDING="2" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 15%"><FONT STYLE="font-size: 10pt"><B>Exhibit No.</B></FONT></TD>
    <TD STYLE="width: 85%"><FONT STYLE="font-size: 10pt"><B>Description</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">99.1</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Press release dated May 12, 2021</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>dp150904_ex9901.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: right; margin: 0"><FONT STYLE="font-size: 10pt"><B>Exhibit 99.1</B></FONT></P>

<P STYLE="margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: right; margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT><IMG SRC="image_001.jpg" ALT=""></P>

<P STYLE="margin: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 14pt Arial, Helvetica, Sans-Serif; margin: 0pt 0pt 3pt; text-align: center">&nbsp;</P>

<P STYLE="font: 14pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>ADC Therapeutics
Announces Online Publication of LOTIS-2 Results in </B>&nbsp;</FONT></P>

<P STYLE="font: 14pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>The Lancet Oncology</B></FONT></P>

<P STYLE="font: 14pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><I>Recent FDA approval
of ZYNLONTA&trade; (loncastuximab tesirine-lpyl) was based on data from LOTIS-2</I></FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><I>ZYNLONTA<SUP>TM
</SUP>demonstrated substantial single-agent activity, durable responses and an acceptable safety profile in broad population of difficult-to-treat
patients with relapsed or refractory DLBCL</I></FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>LAUSANNE, Switzerland, May 12, 2021
</B>&ndash; ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company leading the development of novel antibody drug
conjugates (ADCs) to treat hematological malignancies and solid tumors, today announced that results of LOTIS-2, a multicenter, open-label,
single-arm Phase 2 clinical trial evaluating the safety and efficacy of single-agent ZYNLONTA<SUP>TM</SUP> in adult patients with relapsed
or refractory diffuse large B-cell lymphoma (DLBCL) following two or more systemic treatments, have been published online in <I>The Lancet
Oncology</I>.</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&ldquo;Patients with relapsed or refractory
DLBCL who have been heavily pretreated and have difficult-to-treat disease represent an urgent area of medical need that newly approved
ZYNLONTA is now able to address,&rdquo; said Paolo F. Caimi, MD, University Hospitals Cleveland Medical Center and Case Comprehensive
Cancer Center, Case Western Reserve University and lead author of&nbsp;<I>The Lancet Oncology</I>&nbsp;paper. &ldquo;The LOTIS-2 study
established that ZYNLONTA demonstrated substantial single-agent activity and produced durable responses with an acceptable safety profile
in this patient population.&rdquo;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">LOTIS-2 enrolled 145 patients, including
those with high-risk characteristics for poor prognosis, such as double-/triple-hit, transformed, and primary refractory DLBCL. Key results
include:</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD><FONT STYLE="font-size: 10pt">Overall
                                            response rate (ORR) was 48.3% (70/145 patients), including a 24.1% (35/145 patients) complete
                                            response rate and 24.1% (35/145 patients) partial response (PR) rate</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD><FONT STYLE="font-size: 10pt">Median
                                            time to first response, analyzed post-hoc, was 41 days</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD><FONT STYLE="font-size: 10pt">Median
                                            duration of response was 10.3 months (as of the data cut)</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD><FONT STYLE="font-size: 10pt">Durable
                                            responses in high-risk patient groups included 46.2% (6/13 patients) ORR in those who had
                                            progression after prior CAR-T therapy, 33.3% (5/15 patients) ORR in double or triple hit
                                            and 44.8% (13/29 patients) ORR in transformed DLBCL</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD><FONT STYLE="font-size: 10pt">ZYNLONTA
                                            demonstrated an acceptable safety profile. The most common Grade &ge;3 treatment-emergent
                                            adverse events were neutropenia (25.5%), thrombocytopenia (17.9%), and increased gamma-glutamyltransferase
                                            (16.6%)</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 11pt Arial, Helvetica, Sans-Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&ldquo;We are proud to have the results
of our LOTIS-2 trial published in a prestigious peer-reviewed journal,&rdquo; said Jay Feingold, MD, PhD, Senior Vice President and Chief
Medical Officer at ADC Therapeutics. &ldquo;On the heels of the FDA approval, this further reinforces the value of ZYNLONTA as the first
CD19-targeted ADC single-agent treatment for relapsed or refractory DLBCL and the potential for it to become the standard-of-care for
3L+ DLBCL patients in need of new treatment options.&rdquo;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">The study can be found on <I>The Lancet
Oncology&rsquo;s</I> website at: <FONT STYLE="color: Blue"><U>http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00139-X/fulltext</U></FONT>.</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>About ADC Therapeutics</B></FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">ADC Therapeutics (NYSE: ADCT) is a commercial-stage
biotechnology company improving the lives of cancer patients with its next-generation, targeted antibody drug conjugates (ADCs).&nbsp;The
Company is advancing its proprietary ADC technology to transform the treatment paradigm for patients with hematologic malignancies and
solid tumors.</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">ADC Therapeutics&rsquo; CD19-directed
ADC ZYNLONTA&trade; (loncastuximab tesirine-lpyl) is approved by the FDA for the treatment of relapsed or refractory diffuse large B-cell
lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in late-stage clinical trials in combination with other agents.
Cami (camidanlumab tesirine) is being evaluated in a late-stage clinical trial for relapsed or refractory Hodgkin lymphoma and in a Phase
1b clinical trial for various advanced solid tumors. In addition to ZYNLONTA and Cami, the Company has multiple PBD-based ADCs in ongoing
clinical and preclinical development.</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">ADC Therapeutics is based in Lausanne
(Biop&ocirc;le), Switzerland and has operations in London, the San Francisco Bay Area and New Jersey. For more information, please visit
<FONT STYLE="color: Blue"><U>https://adctherapeutics.com</U></FONT>/ and follow the Company on&nbsp;<FONT STYLE="color: Blue"><U>Twitter</U></FONT>&nbsp;and&nbsp;<FONT STYLE="color: Blue"><U>LinkedIn</U></FONT>.</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">ZYNLONTA&trade; is a trademark of ADC
Therapeutics SA.</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>About ZYNLONTA&trade; (loncastuximab
tesirine-lpyl)</B></FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">ZYNLONTA<SUP>TM </SUP>is a CD19-directed
antibody drug conjugate (ADC). Once bound to a CD19-expressing cell, ZYNLONTA is internalized by the cell, where enzymes release a pyrrolobenzodiazepine
(PBD) payload. The potent payload binds to DNA minor groove with little distortion, remaining less visible to DNA repair mechanisms.
This ultimately results in cell cycle arrest and tumor cell death.</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">The U.S. Food and Drug Administration
(FDA) has approved ZYNLONTA (loncastuximab tesirine-lpyl) for the treatment of adult patients with relapsed or refractory (r/r) large
B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified
(NOS), DLBCL arising from low-grade lymphoma and also high-grade B-cell lymphoma. This indication is approved by the FDA under accelerated
approval based on overall response rate and continued approval for this indication may be contingent upon verification and description
of clinical benefit in a confirmatory trial.</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">The FDA approval was based on data from
LOTIS-2, a large (n=145) Phase 2 multinational, single-arm clinical trial of ZYNLONTA for the treatment of adult patients with r/r DLBCL
following two or more prior lines of systemic therapy. Results from the trial demonstrated an overall response rate (ORR) of 48.3% (70/145
patients), which included a complete response (CR) rate of 24.1% (35/145 patients) and a partial response (PR) rate of 24.1% (35/145
patients). Patients had a median time to response of 1.3 months and the median duration of response (mDoR) for the 70 responders was
10.3 months (inclusive of patients who were censored). In a pooled safety population the most common adverse reactions (&ge;20%) were
thrombocytopenia, gamma-glutamyltransferase increased, neutropenia, anemia, hyperglycemia, transaminase elevation, fatigue, hypoalbuminemia,
rash, edema, nausea and musculoskeletal pain. In LOTIS-2, the most common (&ge;10%) grade &ge;3 treatment-emergent adverse events were
neutropenia (26.2%), thrombocytopenia (17.9%), gamma-glutamyltransferase increased (17.2%) and anemia (10.3%).</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">ZYNLONTA is also being evaluated as a
therapeutic option in combination studies in other B-cell malignancies and earlier lines of therapy.</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>Important Safety Information </B></FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">WARNINGS AND PRECAUTIONS</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Effusion and Edema</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Serious effusion and edema occurred in
patients treated with ZYNLONTA. Grade 3 edema occurred in 3% (primarily peripheral edema or ascites) and Grade 3 pleural effusion occurred
in 3% and Grade 3 or 4 pericardial effusion occurred in 1%.</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Monitor patients for new or worsening
edema or effusions. Withhold ZYNLONTA for Grade 2 or greater edema or effusion until the toxicity resolves. Consider diagnostic imaging
in patients who develop symptoms of pleural effusion or pericardial effusion, such as new or worsened dyspnea, chest pain, and/or ascites
such as swelling in the abdomen and bloating. Institute appropriate medical management for edema or effusions.</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Myelosuppression</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Treatment with ZYNLONTA can cause serious
or severe myelosuppression, including neutropenia, thrombocytopenia, and anemia. Grade 3 or 4 neutropenia occurred in 32%, thrombocytopenia
in 20%, and anemia in 12% of patients. Grade 4 neutropenia occurred in 21% and thrombocytopenia in 7% of patients. Febrile neutropenia
occurred in 3%.</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Monitor complete blood counts throughout
treatment. Cytopenias may require interruption, dose reduction, or discontinuation of ZYNLONTA. Consider prophylactic granulocyte colony-stimulating
factor administration as applicable.</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Infections</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Fatal and serious infections, including
opportunistic infections, occurred in patients treated with ZYNLONTA. Grade 3 or higher infections occurred in 10% of patients, with
fatal infections occurring in 2%. The most frequent Grade &ge;3 infections included sepsis and pneumonia.</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Monitor for any new or worsening signs
or symptoms consistent with infection. For Grade 3 or 4 infection, withhold ZYNLONTA until infection has resolved.</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Cutaneous Reactions</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Serious cutaneous reactions occurred
in patients treated with ZYNLONTA. Grade 3 cutaneous reactions occurred in 4% and included photosensitivity reaction, rash (including
exfoliative and maculo-papular), and erythema.</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Monitor patients for new or worsening
cutaneous reactions, including photosensitivity reactions. Withhold ZYNLONTA for severe (Grade 3) cutaneous reactions until resolution.
Advise patients to minimize or avoid exposure to direct natural or artificial sunlight including exposure through glass windows. Instruct
patients to protect skin from exposure to sunlight by wearing sun-protective clothing and/or the use of sunscreen products. If a skin
reaction or rash develops, dermatologic consultation should be considered.</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Embryo-Fetal Toxicity</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Based on its mechanism of action, ZYNLONTA
can cause embryo-fetal harm when administered to a pregnant woman because it contains a genotoxic compound (SG3199) and affects actively
dividing cells.</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Advise pregnant women of the potential
risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with ZYNLONTA and for 9 months
after the last dose. Advise male patients with female partners of reproductive potential to use effective contraception during treatment
with ZYNLONTA and for 6 months after the last dose.</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">ADVERSE REACTIONS</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">In a pooled safety population of 215
patients (Phase 1 and LOTIS-2), the most common (&gt;20%) adverse reactions, including laboratory abnormalities, were thrombocytopenia,
increased gamma-glutamyltransferase, neutropenia, anemia, hyperglycemia, transaminase elevation, fatigue, hypoalbuminemia, rash, edema,
nausea, and musculoskeletal pain.</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">In LOTIS-2, serious adverse reactions
occurred in 28% of patients receiving ZYNLONTA. The most common serious adverse reactions that occurred in &ge;2% receiving ZYNLONTA
were febrile neutropenia, pneumonia, edema, pleural effusion, and sepsis. Fatal adverse reactions occurred in 1%, due to infection.</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Permanent treatment discontinuation due
to an adverse reaction of ZYNLONTA occurred in 19% of patients. Adverse reactions resulting in permanent discontinuation of ZYNLONTA
in &ge;2% were gamma-glutamyltransferase increased, edema, and effusion.</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Dose reductions due to an adverse reaction
of ZYNLONTA occurred in 8% of patients. Adverse reactions resulting in dose reduction of ZYNLONTA in &ge;4% was gamma-glutamyltransferase
increased.</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Dosage interruptions due to an adverse
reaction occurred in 49% of patients receiving ZYNLONTA. Adverse reactions leading to interruption of ZYNLONTA in &ge;5% were gamma-glutamyltransferase
increased, neutropenia, thrombocytopenia, and edema.</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">You may report side effects to the FDA
at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to ADC Therapeutics at 1-855-690-0340.</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Please see full Prescribing Information
at www.ZYNLONTA.com for ZYNLONTA.</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>Forward-Looking Statements</B></FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">This press release contains statements
that constitute forward-looking statements. All statements other than statements of historical facts contained in this press release,
including statements regarding our future results of operations and financial position, business and commercialization strategy, products
and product candidates, research pipeline, ongoing and planned preclinical studies and clinical trials, regulatory submissions and approvals,
addressable patient population, research and development costs, timing and likelihood of success, as well as plans and objectives of
management for future operations are forward-looking statements. Forward-looking statements are based on our management&rsquo;s beliefs
and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and
actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including
those described in our filings with the U.S. Securities and Exchange Commission. No assurance can be given that such future results will
be achieved. Such forward-looking statements contained in this document speak only as of the date of this press release. We expressly
disclaim any obligation or undertaking to update these forward-looking statements contained in this press release to reflect any change
in our expectations or any change in events, conditions, or circumstances on which such statements are based unless required to do so
by applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-size: 10pt"><B>CONTACTS</B></FONT></P>

<P STYLE="font: 11pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>Investors</B><BR>
Eugenia Litz&nbsp;</FONT></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">ADC Therapeutics&nbsp;</FONT></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt; color: Blue"><U>Eugenia.Litz@adctherapeutics.com</U>&nbsp;</FONT></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Tel.: +44 7879 627205</FONT></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Amanda Hamilton<BR>
ADC Therapeutics<BR>
<FONT STYLE="color: Blue"><U>amanda.hamilton@adctherapeutics.com</U></FONT><BR>
Tel.: +1 917 288 7023</FONT></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>EU Media</B><BR>
Alexandre M&uuml;ller<BR>
Dynamics Group<BR>
<FONT STYLE="color: Blue"><U>amu@dynamicsgroup.ch</U></FONT><BR>
Tel: +41 (0) 43 268 3231</FONT></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>USA Media </B><BR>
Annie Starr<BR>
6 Degrees<BR>
<FONT STYLE="color: Blue"><U>astarr@6degreespr.com</U></FONT><BR>
Tel.: +1 973-768-2170</FONT></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" != *<# 2(  A$! Q$!_\0
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M2?\ $MM&(CQTD;N_]![?6NC#4'6G;IU,,165*%^I>?XR^(R[%(+%5).!Y;'
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M+I.+=1V9P8C.8QDE15UU_P" ?35%<?\ #_5=:U32V?4T#0)Q#.W#R?X@>O\
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MG;VK*%>*7,WMOOY_KV-JF&FWRJ/Q+3;R?Y=R\LEW=Q73)=>289Y%&V,-E1C
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@"A5>2^[!R3QTQZ45M0GSPNMOZ[F.)@X5.5Z/^NVA_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
